Etiome

Etiome, founded in 2021 and originating from Flagship Pioneering, is developing a novel AI-driven platform to map the continuum of disease progression from silent, early stages to advanced disease. The company's core thesis is that therapies tailored to specific biological stages of a disease will be more effective than traditional one-size-fits-all approaches, potentially slowing, preventing, or reversing damage. Led by a seasoned biotech executive, Adrian Rawcliffe, Etiome is in the pre-clinical discovery phase, building its proprietary platform and target pipeline with the backing of its venture creator. The company operates as a private, pre-revenue entity aiming to disrupt the therapeutic paradigm for chronic and progressive diseases.

Proprietary AI-driven platform integrating single-cell omics to model disease progression, identify stage-specific therapeutic targets, and discover dynamic biomarkers for patient stratification.

Etiome competes in the crowded AI-driven drug discovery space with companies like Recursion, Insitro, and Exscientia. Its specific focus on temporal disease staging differentiates it, but it faces competition from both pure-play AI biotechs and large pharma internal efforts. Success will depend on demonstrating superior biological insights that translate into clinical assets.